Search - tctmd.com

Displaying 581 - 600 of 818

Sort: Relevancy | Date

Presentation TCT 2016

Overview of the Clinical Trials for Drug-Coated Balloons

Presenter: Schuyler Jones, Misti Malone, George Papandreou

October 30, 2016

News Conference News TCT 2016

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

Yael L. Maxwell

October 30, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

ILUMIEN 3: OCT Imaging Matches IVUS but Fails To Beat Angiography for Stent Guidance in PCI

News Conference News TCT 2016

ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI

Shelley Wood

October 30, 2016

News Conference News TCT 2016

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

Todd Neale

October 29, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Opinion Editor's Corner TCT 2015

My Takeaways From TCT 2015

Shelley Wood

October 20, 2015

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

Presentation TCT 2015

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Presenter: Martin B. Leon, Nicolo Piazza, Hendrik Treede

October 14, 2015

Presentation TCT 2015

Reversal Agents for Factor Xa Inhibitors

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2015

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe, Manesh R. Patel

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Advertisement

Overview of the Clinical Trials for Drug-Coated Balloons

LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI

Impella CP Fails to Show Benefit in Exploratory Study of Patients With Severe Cardiogenic Shock

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

My Takeaways From TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

CE-Approved or EU Studies: JenaValve Technology Review and Clinical Update (JUPITER Trials)

Reversal Agents for Factor Xa Inhibitors

Rivaroxaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content